380 results on '"Dalbeni, Andrea"'
Search Results
2. Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma
3. Hepatofugal portal flow is highly predictive of acute-on-chronic liver failure: A new hemodynamic patho-physiological hypothesis
4. Metabolic-associated fatty liver disease and liver fibrosis scores as COVID-19 outcome predictors: a machine-learning application
5. Spur cells in liver cirrhosis are predictive of acute-on-chronic liver failure and liver-related mortality regardless of severe anaemia
6. Bacterial infections as a risk factor for non-neoplastic portal vein thrombosis development in cirrhotic patients
7. The impact of COVID-19 pandemic on well-being of Italian physicians: a report from the Italian Society of Internal Medicine (SIMI) national survey
8. Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension
9. How to ‘SAVE’ antibiotics: effectiveness and sustainability of a new model of antibiotic stewardship intervention in the internal medicine area
10. Performance of non-invasive respiratory function indices in predicting clinical outcomes in patients hospitalized for COVID-19 pneumonia in medical and sub-intensive wards: a retrospective cohort study
11. Global Longitudinal Strain to Predict Respiratory Failure and Death in Patients Admitted for COVID-19–Related Disease
12. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
13. FRI-290 Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness
14. THU-472-YI Sorafenib as a second-line treatment after failure of Atezolizumab/Bevacizumab
15. THU-471-YI From randomised clinical trials to clinical practice: a systematic reviewand meta-analysis of real-word data on atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
16. FRI-279-YI Platelet dynamics in metabolic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and liver cirrhosis
17. SAT-477-YI The impact of etiologyon patterns of progression of advanced HCC
18. FRI-226 The impact of light to moderate alcohol consumption on liver and cardiovascular damage in metabolic-dysfunction associated steatotic liver disease
19. Percutaneous ablation in perivascular-HCC: impact of liver parenchyma and characteristics of vascular structures on the outcomes.
20. Multifocal Hepatic Angiosarcoma with Atypical Presentation: Case Report and Literature Review
21. Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome
22. Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with non alcoholic fatty liver disease
23. Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis
24. Traditional cardiovascular risk factors and residual disease activity are associated with atherosclerosis progression in rheumatoid arthritis patients
25. The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases
26. Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis
27. Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies—A Case-Control Study
28. Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility.
29. Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
30. Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
31. QTc Prolongation to Predict Mortality in Patients Admitted with COVID- 19 Infection: An Observational Study
32. Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies
33. Author's Reply: “Bacterial infections predispose to the development of portal vein thrombosis in patients with decompensated cirrhosis”
34. Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis
35. Lycopene inhibits endothelial cells migration induced by vascular endothelial growth factor A increasing nitric oxide bioavailability
36. Individual fatty acids in erythrocyte membranes are associated with several features of the metabolic syndrome in obese children
37. COVID-19 outbreak in children and/or adolescents
38. Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population
39. Editorial: The NAFLD-MAFLD conundrum
40. Bacterial infections as a risk factor for non-neoplastic portal vein thrombosis development in cirrhotic patients
41. Prognostic Role of Subclinical Left Ventricular Systolic Dysfunction Evaluated by Speckle-Tracking Echocardiography in Rheumatoid Arthritis
42. Predictors and prognostic role of low myocardial mechano-energetic efficiency in chronic inflammatory arthritis
43. Metabolic associated fatty liver disease: different impact of the three defining criteria on the hepatic and cardiovascular complications
44. It takes a team for HCC: improvement of outcome with the multidisciplinary ambulatory for systemic therapy
45. Cholestatic HCV-related cryoglobulinemia, a new clinical and pathological entity: a case-control study
46. Glomerular hyperfiltration: a new marker of fibrosis severity in non-cirrhotic non-alcoholic fatty liver disease
47. Spur cells in liver cirrhosis are predictive of ACLF and liver-related mortality regardless of severe anaemia
48. Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction in Patients with Rheumatoid Arthritis without Overt Cardiac Disease
49. Coronavirus disease 2019 (COVID-19): we don’t leave women alone
50. Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.